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Hepatitis C virus (HCV) infection frequently persists despite substantial virus-specific 
cellular immune responses. To determine if immunologically driven sequence variation 
occurs with HCV persistence, we coordinately analyzed sequence evolution and CD8
 
 
 
 T cell 
responses to epitopes covering the entire HCV polyprotein in subjects who were followed 
prospectively from before infection to beyond the first year. There were no substitutions in 
T cell epitopes for a year after infection in a subject who cleared viremia. In contrast, in 
subjects with persistent viremia and detectable T cell responses, we observed substitutions
in 69% of T cell epitopes, and every subject had a substitution in at least one epitope. In 
addition, amino acid substitutions occurred 13-fold more often within than outside T cell 
epitopes (P 
 
 
 
 0.001, range 5–38). T lymphocyte recognition of 8 of 10 mutant peptides 
was markedly reduced compared with the initial sequence, indicating viral escape. Of 16 
nonenvelope substitutions that occurred outside of known T cell epitopes, 8 represented 
conversion to consensus (P 
 
 
 
 0.015). These findings reveal two distinct mechanisms of 
sequence evolution involved in HCV persistence: viral escape from CD8
 
 
 
 T cell responses and 
optimization of replicative capacity.
 
The World Health Organization estimates
there are 170 million persons with hepatitis C
virus (HCV) infection worldwide, and an esti-
mated 4 million persons are infected with
HCV in the United States (1, 2). In most
countries, HCV infection is found in 1–2% of
the general population and may cause cirrhosis
or hepatocellular cancer, but only when infec-
tion persists (3–7).
Patients in the acute phase of HCV infection
are much more likely to respond to therapy that
is designed to eradicate the virus than are patients
after progression to chronicity (8–10). The
features unique to acute infection that allow
increased responsiveness to interferon therapy
remain unknown. Spontaneous clearance of
HCV infection occurs in 
 
 
 
20% of acutely
infected individuals and is associated with a
broadly specific and vigorous cellular immune
response (11–14). Although the cellular immune
response is often less vigorous and more nar-
rowly directed in those who fail to clear the
infection, nonetheless, a cellular immune re-
sponse often is present in early infection and
may persist into chronic infection. Why the
early response fails to control viremia in those
who progress to chronic infection is not clear,
but responses generated in acute infection
have been shown to decline in some sub-
jects who remained persistently infected, and
chronic infection is characterized by low fre-
quencies of CD8
 
 
 
 T cells in peripheral blood
(13, 15–20). Although the liver has the poten-
tial to delete antigen-specific T cell responses,
HCV-specific CD8
 
 
 
 CTL lines have been
generated from the liver of chronically in-
fected humans and chimpanzees; this suggests
that elimination of HCV-specific lymphocytes
from the liver is neither universal nor neces-
sary for HCV persistence (21–24). Survival of
HCV, despite virus-specific CD8
 
 
 
 CTL, might
be explained by impaired cellular effector
functions (proliferation, cytokine secretion,
cytolytic activity), T cell exhaustion, or den-
dritic cell dysfunction (16, 25–27). A final
possibility is that persistence is facilitated by
viral evolution over the course of infection,
enabling escape by mutation of key epitopes
targeted by T lymphocytes. Mutational escape
from T cell responses has been noted in HIV,
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which uses an error-prone RNA polymerase similar to
HCV (28).
Mathematical models of viral kinetics suggest that up to
10
 
12
 
 virions are produced each day in a human with chronic
hepatitis C (29). This rate exceeds comparable estimates of
the production of HIV by more than an order of magnitude,
and, coupled with the absence of proofreading by the HCV
NS5B RNA polymerase, results in frequent mutations
within the HCV genome. Mutation of class I or II MHC re-
stricted T cell epitopes could alter the outcome of infection
by preventing or delaying clearance of infected hepatocytes
(30). In the face of a vigorous multispecific CTL response,
mutation of several epitopes, perhaps simultaneously, would
be required for survival of the virus. In HCV infection, a
strong association between viral persistence and the develop-
ment of escape mutations has been demonstrated in the
chimpanzee model (31), and one group examined viral evo-
lution in a single HLA-B8–restricted NS3 epitope (32);
however, evidence of evasion of a multispecific CTL re-
sponse in humans is lacking. Although mutations in class I
MHC-restricted HCV epitopes have been observed in hu-
mans with chronic HCV infection, it is uncertain that these
mutations result from CD8
 
 
 
 T cell selection pressure or that
they occur during the acute phase of infection, when clear-
ance or persistence is determined (33–35).
Studies of the cellular immune response to acute HCV
infection have been challenging because acute hepatitis C
usually is clinically silent; this makes early virus isolates and
CTL difficult to obtain. In addition, no consistent pattern of
HCV epitope dominance has emerged in humans so large
numbers of PBMCs are needed for the broad screening that
is required to identify CTL responses. We have overcome
these challenges to test the hypothesis that CTL-driven se-
quence variation occurs with progression to persistent HCV
in humans. We prospectively studied HCV antibody-nega-
tive injection drug users at risk for HCV infection and com-
pared the viral sequences at initial viremia to sequences that
were obtained at multiple time points in acute HCV infec-
tion. In parallel, a genome-wide analysis of T cell respon-
siveness was performed. As evidence of immune selection
pressure, we determined the percentage of T cell epitopes
that underwent substitution, assessed the likelihood of amino
acid changing substitutions to occur within versus outside T
cell epitopes, and examined the effects of observed amino
acid sequence changes in epitopes on T cell recognition and
MHC class I binding. For amino acid substitutions outside T
cell epitopes, we investigated explanations other than T cell
pressure. Our results provide strong evidence in humans that
immune and fitness selection occur during the acute phase of
HCV infection.
 
RESULTS
 
We assessed T cell responses using IFN-
 
 
 
 ELISPOT, and se-
quenced half of the HCV genome in eight subjects, seven of
whom progressed to chronic infection (Fig. 1). For five sub-
Figure 1. Fluctuating HCV RNA level during acute infection. Spon-
taneous clearance (SC) occurred in one subject, and persistence developed 
in seven others. A solid triangle indicates detectable HCV RNA. An open 
triangle indicates an HCV RNA level of less than 50 IU/ml. A gray inverted 
triangle indicates that IFN-  ELISPOT analysis of T cell responses was per-
formed at that time point. The number in the bottom right corner of each 
panel is the subject number. Subject 28 entered the study antibody nega-
tive and HCV RNA positive so that the time of infection is estimated using 
the average time from infection to seroconversion. 
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jects [17, 18, 21, 28, 29], large numbers of PBMCs were
available and permitted comprehensive screening by using
overlapping peptides. Three subjects (11, 12, 13) with fewer
PBMCs were screened for responses at all sites of amino acid
replacements. T cell and viral analyses were done for all eight
at initial detection of viremia and then 6 mo later. Additional
assessment of T cell responses was done at the time points
designated by arrows in Fig. 1. No T cell responses were de-
tectable at initial viremia, but all of the subsequently de-
tected T cell responses were present by 6 mo after infection.
T cells that responded to peptides that were longer than 10
amino acids were confirmed as CD8
 
 
 
 positive by bead de-
pletion and/or intracellular cytokine staining.
 
Persistence versus loss of T cell epitopes with 
sequence evolution
 
The locations of amino acid substitutions and recognized
CD8
 
 
 
 T cell epitopes within the portion of the genome that
was sequenced are shown in Fig. 2. Comprehensive screen-
ing for CD8
 
 
 
 T cell responses in subjects 17, 18, 21, 28, and
29 revealed responses in all except subject 21. The only sub-
ject (18) who cleared HCV spontaneously also was the only
individual whose HCV genome had no substitutions within
any recognized T cell epitope at 6 or 12 mo after initial vire-
mia. Subjects 17, 28, and 29 remain persistently infected and
had substitutions at 6 mo in 3 of 5, 6 of 8, and 2 of 3 recog-
nized CD8
 
 
 
 T cell epitopes, respectively. This difference
Figure 2. Amino acid substitutions and epitopes recognized during 
the first 6 mo of HCV infection for five subjects. The map at the top 
of the figure indicates the region of the HCV polyprotein sequenced. For 
each study subject, horizontal lines represent the sequences obtained at 
initial viremia (t0), 6 mo after viremia was first detected (t6), and 12 mo 
after viremia was first detected (t12). Thin vertical lines represent amino 
acid substitutions. Shorter, thicker vertical lines indicate recognized 
epitopes, below which the t0 and t6 sequences of the epitope are shown. 
Subject 29 had no detectable response to the t0 peptide HSKRKCDEL, but 
did respond to the t6 peptide; therefore, this was not counted as an escape 
mutation in subsequent analyses. *Subjects 11, 12, and 13 were not tested 
for IFN-  responses using the entire panel of 524 peptides because of 
limited PBMC specimens; instead, they were screened using peptides over-
lapping sites of amino acid replacement. 
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was not explained by lower levels of replication in subject
18, whose mean log
 
10
 
 RNA level during the first 6 mo of in-
fection (3.8) was higher than that of two subjects with
epitope substitutions (17 at 2.8, and 13 at 3.4). Comparing
RNA levels and the number of substitutions in all 8 subjects
revealed no correlation between the number of substitutions
in epitopes or overall, and the level of viremia (unpublished
data). Additional sequencing at 12 mo of viremia revealed 12
amino acid replacements, none of which occurred in subject
18’s three recognized epitopes. In summary, the subject who
cleared infection had no substitutions in three recognized T
cell epitopes at 6 mo or 12 mo after infection, whereas the
three subjects with chronic viremia and T cell responses had
substitutions in 60–75% of CD8
 
 
 
 T cell epitopes by 6 mo
after infection.
 
Impact of amino acid substitutions on T cell recognition
 
T cell lines were generated from PBMCs using synthetic
peptides which represented the viral sequences that were
present at initial viremia (t
 
0
 
). To assess the impact of amino
acid substitutions on T cell recognition, those T cell lines
and bulk PBMCs that were obtained 
 
 
 
6 mo after initial
viremia were tested for IFN-
 
 
 
 production in response to se-
rial dilutions of the t
 
0
 
 peptide or a synthetic peptide which
represented the viral sequence that was present at 6 mo after
initial viremia (t
 
6
 
). Ten t
 
0
 
/t
 
6
 
 peptide pairs from subjects with
persistent viremia were tested using T cell lines or PBMCs;
three patterns were observed (Fig. 3). For the 10 t
 
6
 
 peptides
that were tested, we noted loss of recognition of four (Fig. 3
A), decreased recognition of four others (Fig. 3 B), and com-
parable recognition of two (Fig. 3 C). Therefore, for 8 of the
10 mutations in recognized epitopes that were tested, recog-
nition by T lymphocytes was lost or significantly reduced
compared with recognition of the sequence that was present
at initial viremia, indicating escape. In no case was the t
 
6
 
variant peptide recognized better than the t
 
0
 
 peptide. For 4
t
 
0
 
/t
 
6
 
 peptide pairs that also were tested with bulk PBMCs,
the patterns of recognition were similar to those observed
Figure 3. Amino acid substitutions in epitopes reduced T cell 
responses. Peptide sequences that were observed to vary between t0 
(circle, initial viremia) and t6 (triangle, 6 mo after onset of viremia) were 
used as antigens in IFN-  ELISPOT, using PBMCs (filled symbols) or T cell 
lines generated from PBMCs (open symbols) obtained at t6 as effectors. 
(A) Loss of recognition: For 4 of 10 peptide pairs, recognition of the t6 
variant peptide was reduced at least 20-fold at all concentrations. (B) De-
creased recognition: For 4 of 10 peptide pairs, recognition of the t6 variant 
peptide was reduced more than 2-fold but less than 20-fold at at least 
two concentrations of peptide. (C) Comparable recognition: For 2 of 10 
pairs of peptides, recognition of the t6 variant was not reduced more than 
twofold relative to the t0 peptide at more than one concentration tested. 
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using T cell lines, as shown in Fig. 4. That PBMCs and T
cell lines that were generated against the t
 
0
 
 peptides failed to
recognize the t
 
6
 
 peptides suggests that the substitution allows
escape from the T cells that are specific for the original se-
quence, and that no new T cell responses were generated
against the t
 
6
 
 sequence.
To rule out transient suppression or problems with speci-
men handling and the subsequent development of T cell re-
sponses to the t
 
6
 
 HCV sequence, IFN-
 
 
 
 ELISPOT testing for
recognition of the t
 
6
 
 peptides that demonstrated escape also
was performed in subjects 17 and 28 using PBMCs that were
obtained 
 
 
 
12, 18, 24, and (in subject 17) 36 mo after initial
infection. The patterns of recognition persisted over time and
recognition of the t
 
6
 
 peptides declined in parallel with the de-
cline in recognition of the t
 
0
 
 peptides that occurred with pro-
longed infection (Fig. 5). Despite months of persistent expo-
sure to the t
 
6
 
 peptides that escaped recognition at 6 mo after
infection, in no case did a new T cell response specific for a t
 
6
 
peptide arise in the following 6 to 36 mo.
 
Mechanisms of loss of T cell recognition with 
amino acid substitutions
 
Amino acid substitutions may result in decreased recognition
through reduced HLA-binding capacity, abrogation of T cell
recognition, or altered processing with failure to generate
the correct sequence for presentation on the surface. We did
observe marked reduction in HLA-binding capacity as one
mechanism for reduced recognition in our subjects. For ex-
ample, the HLA A*0101–restricted ATDALMTGY epitope
that was recognized at t
 
0
 
 by subject 28 had an A*0101-bind-
ing capacity (IC
 
50
 
) of 0.24 nM, whereas the ATDALMTGF
peptide that was recognized at t
 
6
 
 had a binding capacity of
64 nM. A fivefold difference in binding capacity is consid-
ered significant; thus the 267-fold decrease in binding capac-
Figure 4. Similar recognition patterns using lines and PBMCs. 
IFN-  ELISPOT responses for T cell lines (open symbols) and PBMCs (closed 
symbols) from which the lines were generated using the t0 peptide are 
shown. Responses for PBMCs and T cell lines were consistently similar 
aside from the expected differences in the proportion of responding cells 
(note difference in axes). 
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ity that was observed for the variant peptide indicates a
markedly reduced HLA-binding capacity. However, the
HLA A*0201–restricted KLVALGINAV epitope that was
recognized at t
 
0
 
 by subject 28 had an A0201-binding capac-
ity of 5.0 nM, whereas the KLVAMGINAV peptide that
was recognized at t
 
6
 
 had a binding capacity of 2.3 nM—an
insignificant difference that, if anything, favors the less well-
recognized peptide, t
 
6
 
. This t
 
6
 
 peptide may stimulate less
IFN-
 
 
 
 production in the ELISPOT assay because of de-
creased T cell recognition rather than reduced HLA-binding
capacity. Although 2 of the 10 t
 
0
 
/t
 
6
 
 peptide pairs were rec-
ognized comparably, we cannot rule out that they also rep-
resent escape mutations because substitutions were shown by
others to result in altered processing such that the peptide is
no longer presented on the cell surface (32, 36–38). We did
not observe the Y1082F substitution that recently was re-
ported to abrogate proteasomal processing of the HLA A*02
1073–1081 epitope (38). This mode of escape is circum-
vented when peptides are loaded onto the surface of the cell,
as in an ELISPOT assay.
 
Driving forces for sequence evolution
 
We next evaluated the proportion of substitutions that oc-
curred in observed T cell epitopes and investigated explana-
tions for substitutions outside of T cell epitopes. Of 69 sub-
stitutions that were observed in the eight subjects, 17 (25%)
occurred within detected CD8
 
 
 
 T cell epitopes, 36 (52%)
occurred in envelope proteins (likely antibody targets), and
Figure 5. Recognition patterns persist with time. To rule out the 
subsequent development of T cell responses to the t6 HCV sequence, IFN-  
ELISPOT testing for recognition of the t6 peptides demonstrating escape 
also was performed for subjects 17 and 28 using PBMCs that were 
obtained  12, 18, 24, and—for subject 17—36 mo after initial infection. 
The number in the bottom right corner of each panel is the subject num-
ber. Patterns of recognition persisted over time and recognition of the t6 
peptides ( ) declined in parallel with the decline in recognition of the t0 
peptides ( ) that occurred with prolonged infection. 
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16 (23%) occurred outside of envelope regions and T cell
epitopes. In the five subjects [17, 18, 21, 28, 29] with suffi-
cient PBMCs for comprehensive IFN-
 
 
 
 ELISPOT screen-
ing, amino acid substitutions were a median of 13-fold more
likely to occur within T cell epitopes than outside of
epitopes (P 
 
 
 
 0.001, range 5–38). Even though at a popula-
tion level the envelope proteins are highly diverse, amino
acid substitutions in T cell epitopes exceeded those in enve-
lope glycoprotein 1 (E1) and envelope glycoprotein 2 (E2)
by sevenfold (P 
 
 
 
 0.001, range 4–14), and the rate of change
in epitopes was comparable to the rate in hypervariable re-
gion 1 (HVR1), which is the most diverse region of HCV
(0.056 in epitopes, 0.074 in HVR1).
It is likely that some CD8
 
 
 
 T cell responses were not de-
tected by the methods that we applied, either because they
were low-level or sequestered in the liver. Thus, we also ex-
amined amino acid substitutions with respect to potential
epitopes, defined as those published (16) and restricted by
HLA alleles possessed by each subject, but not detected by
our methods. This resulted in the examination of 7–33 (total
155) epitopes for amino acid replacements between t
 
0
 
 and t
 
6
 
.
Four amino acid replacements were identified among these
1408 sites, yielding a rate of 0.0028 substitutions per site; this
is 20-fold lower than the rate for epitopes detected in this
study (0.056), and comparable to the background rate of
change at nonepitope sites (0.0042). All four of these substi-
tutions were in envelope (E1 or E2) and three were in
HVR1, regions which are regarded widely as targets of hu-
moral immunity. Taken together, these results indicate that
amino acid replacements were not common in epitopes that
have been described previously, but to which we did not de-
tect an IFN-
 
 
 
 response.
Of the 16 amino acid substitutions that were observed
outside of the envelope proteins or recognized T cell
epitopes in these eight study subjects (Table I), 8 represented
conversion to the most commonly observed residue in refer-
ence sequences (i.e., convergence to the consensus se-
quence). If each site had 19 equally likely alternative amino
acids, the observed change to the single most commonly ob-
served residue at 50% of sites would be extraordinarily un-
likely (P 
 
 
 
 0.015, Table II); this suggests that these changes
were constrained highly. In addition, these convergent
changes were not consistently conservative changes; this ar-
gues against simple structural or functional constraint. These
data are consistent with an accompanying study of chronically
infected individuals for whom the inoculum sequence was
known (39). That study showed that substitutions that oc-
curred in known epitopes for which the infected individual
lacked the presenting HLA allele consistently were reversions
toward the worldwide consensus sequence for subtype 1b.
 
DISCUSSION
 
In this investigation of sequence variation in T cell epitopes
as a potential mechanism for viral persistence, we show that
amino acid substitutions during acute HCV infection are
nonrandom and may be explained, in part, by escape from
CD8
 
 
 
 T cell recognition and convergence, possibly because
of replicatively unfit substitutions that were selected in a pre-
Table I. Nonepitope, nonenvelope changes frequently result in modal residuea
Siteb Region Subject
Change during acute infection
(t0 → t6)c Subtype 1ad Change relative to modal residuee
6 core 11 N → K K102Y2 toward
88 core 17 S → N N128 toward
840 NS2 21 S → G S10A1 away
856 NS2 17 L → Q Q6H2L1 toward
859 NS2 21 V → E V9 away
861 NS2 21 V → I V7I1F1 away
899 NS2 17 F → L L9 toward
908 NS2 13 K → R K9 away
945 NS2 12 T → A T9 away
1021 NS2 12 K → E K9 away
1113 NS3 17 T → A A73T1P1V1 toward
1278 NS3 18 I → L I78S1 away
1314 NS3 12 V → I I49F1 toward
1338 NS3 18 S → T T46 toward
1600 NS3 21 P → L P50L1 away
1648 NS3 28 G → C C54Y1 toward
aChanges that were not located in demonstrated epitopes and not located in the envelope region (Fig. 2).
bPosition in H77 polyprotein (GenBank/EMBL/DDBJ accession no. AF009606).
cAmino acids inferred from cDNA clones obtained at t0 and t6, respectively. Changes were only inferred when independent cDNA clone sequences were in agreement. Under-
lined residues match modal (most frequently observed) residue in the next column.
dSubscripts indicate number of HCV subtype 1a sequences in the Los Alamos National Laboratory database with the indicated amino acid at that position.
eToward, change is from nonmodal residue to modal residue; away, change is from modal residue to nonmodal residue.CELLULAR IMMUNE SELECTION AND HCV PERSISTENCE | Cox et al. 1748
vious host. Significantly, there is early fixation of the T cell
repertoire because we observed no instances of de novo de-
velopment of T cells that recognized mutant t6 epitopes bet-
ter than the original t0 epitope using lines or PBMCs.
Using the chimpanzee model of HCV infection, muta-
tion of multiple class I MHC-restricted epitopes early in the
course of chronic HCV infection was demonstrated (31).
The role of CD8  CTL in control of HCV replication was
reinforced further by a statistically significant increase in the
number of mutations that resulted in amino acid changes
in class I MHC-restricted epitopes, but not unrestricted
epitopes or flanking sequences of the viral genome. These
data indicate that in chimpanzees, amino acid substitutions in
class I MHC-restricted epitopes are selected and possibly
maintained by HCV-specific CD8  CTL populations that
exert positive Darwinian selection pressure.
We also observed a statistically significant increase in the
number of mutations that resulted in amino acid changes in
class I MHC restricted epitopes versus portions of the viral
genome outside T cell epitopes, and that amino acid substi-
tutions in class I MHC-restricted epitopes resulted in escape
from CD8  T cell recognition in acutely HCV-infected hu-
mans who progressed to chronic infection. New T cells spe-
cific for the sequences that were detected 6 mo after initial
viremia were not detected, despite follow-up for as long as 3
yr after infection. Thus, selection of HCV variants that
evade CD8  T cell recognition may represent a mechanism
for persistence of HCV infection in humans. Supporting
this, we observed no substitutions within recognized CD8 
T cell epitopes in the subject who cleared infection, and sub-
stitution in 60–75% of CD8  T cell epitopes in subjects with
persistent infection. The number of CTL epitopes with sub-
stitutions was shown previously to correlate with control of
HIV viremia (28); however, a relationship between HCV
control and maintenance of T cell epitopes had not been
shown previously.
Although the observed substitutions were disproportion-
ately contained within the portion of the HCV polyprotein
in T cell epitopes, many were found outside of detectable T
cell epitopes. It is possible that we missed CD8  T cell
epitopes and that some of the substitutions that were ob-
served outside of T cell epitopes actually represented substi-
tutions within T cell epitopes. We took several steps to min-
imize the chances of this occurring. Where there were
substitutions and the H77 sequence that was used to make
overlapping peptides as potential antigens differed from that
of the subject, we tested for recognition of overlapping pep-
tides representing autologous sequence. Where the subject’s
sequence matched H77 in areas of amino acid substitution,
but there no responses were detected, we tested for recogni-
tion of additional overlapping peptides with different termini
to minimize the possibility that we cut within a region that
contained an epitope. We detected no additional epitopes
via ELISPOT analysis with either method of antigen modifi-
cation (unpublished data).
Because there is no clinical indication for liver biopsy in
acute infection, we could only assess responses in the periph-
ery. Therefore, it is possible that some of the substitutions
may represent pressure for T cell responses present in the
liver but not detectable in the periphery. We do not favor
this explanation because previous studies have shown that
the majority of T cell responses in the liver also are detect-
able in the peripheral blood (40, 41).
There are several possible alternative mechanisms for se-
lection of these substitutions occurring outside of observed
CD8  T cell epitopes. The first is that they represent substitu-
tions in CD4  T cell epitopes. Although we detect a few
CD4  T cell epitopes using our ELISPOT assay, the condi-
tions of the assay preferentially detect CD8  T cell epitopes
and we may fail to detect all of the possible CD4  T cell
epitopes. The second possible explanation is that they repre-
sent substitutions in B cell epitopes. Mutations in dominant
antibody epitopes that are located in the HVR-1 of envelope
glycoprotein 2 (E2) have been linked to persistence of HCV
infection (42). B cell epitopes are predicted to occur within
the envelope regions of the polyprotein and the majority of
mutations outside of T cell epitopes were found in the enve-
lope proteins for most subjects. Another possible explanation
is that the mutations outside of T cell epitopes are selected be-
cause they confer a viral replication advantage. Some muta-
tions may represent epitopes that are recognized by the previ-
ous host that revert to a more stable sequence when the new
host fails to mount similar immune pressure. This may occur
when the new host lacks the MHC allele that is required to
present that epitope. Loss of escape mutations upon passage of
simian immunodeficiency virus to new animals (43) and HIV
to humans (44), that do not exert immune pressure on that
region was described recently, with the inference that escape
from CTL responses may reduce viral fitness.
The relevance of those studies to human infection with
HCV is supported by a recent study of one epitope in an
acutely HCV infected patient (32), and our accompanying
study of chronically infected individuals (39). The former
study supports the nonrandom nature of reversion at a site of
previous immune escape. The latter study shows that HCV
amino acid sequence tends to revert to consensus in areas
outside of T cell epitopes in subjects who have persistent in-
fection. The consensus sequence likely represents a more rep-
licatively fit state than the initial infecting strains, which pre-
Table II. Observed versus expecteda frequencies of change to 
modal residue at 16 sites not located in epitopes nor in 
envelope (E1 or E2) genes
Expected Observed
Change to modal residue 16b (1/19)   0.8 ≈ 18 b
Change to nonmodal residue 16b (18/19)   15.2 ≈ 15 8
aBased on the null hypothesis that all amino acids are equally likely at each position.
bP   0.015.JEM VOL. 201, June 6, 2005 1749
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sumably have adapted to the immune response of the
previous host. Taken together, these results reveal at least two
types of sequence variation that occur simultaneously in pro-
gression of acute HCV to persistence: immune pressure that
selects T cell escape variants, and reversion to consensus se-
quence that is likely to result in enhanced replicative fitness.
Despite viral mutation that results in the production of
new potential antigens, no new T cell responses developed
in response to mutant peptides that escaped initial recogni-
tion over months, and in some cases years, after the appear-
ance of the mutation. This phenomenon also has been ob-
served frequently with HIV sequence evolution where the
failure to prime new responses may be due to impaired
CD4  T cell function. Although overall CD4  T cell func-
tion is intact in HCV infection, chronic HCV infection has
been linked to loss of HCV-specific CD4  T cell responses
(45). In addition, HCV has been linked to impaired DC
function, decreased IFN regulatory factor 3 signaling, and
protein kinase RNA-activated inhibition, which may inhibit
priming of an immune response to the mutated peptides (26,
27, 46, 47). However, the failure to prime responses to the
newly generated sequences is observed even in HIV infected
individuals with relatively high CD4 counts, and there is no
evidence in those with HCV infection of impaired priming
of immune responses to other antigens, as would be evident
by global immunosuppression. An alternative explanation is
that original antigenic sin (the higher threshold required for
stimulation of an immune response to an epitope resembling
a previously recognized epitope [48]) may be responsible for
the lack of response to mutant sequences seen in HIV and
HCV, although this phenomenon has not been demon-
strated in humans. Lastly, because the selective pressures of
the immune system favor the emergence of a viral sequence
that fails to elicit a productive response, we may be observ-
ing sequences that cannot be processed effectively for pre-
sentation or that resemble self-antigens, and therefore, are
incapable of stimulating an immune response.
This study suggests a mechanistic linkage between viral
sequence variation and progression to chronicity. The ar-
rested development of new T cell responses, despite ongoing
viremia with sequence evolution, distinguishes the acute and
chronic phases of HCV infection. Enhanced understanding
of cellular immune failure that leads to chronic HCV infec-
tion could accelerate development of vaccines to prevent vi-
ral persistence, as was suggested elsewhere (39).
MATERIALS AND METHODS
Participants
The Risk Evaluation Assessment of Community Health prospective study
of young injection drug users in Baltimore examined the incidence and risk
factors for HCV infection, as described previously (49). Participants who
were eligible for the study were anti-HCV antibody negative, between 15
and 30 years of age, and acknowledged use of injection drugs. Participants
were invited to co-enroll in a substudy of acute hepatitis C; those who con-
sented had blood drawn for isolation of serum, plasma, and PBMCs in a
protocol that was designed for monthly follow-up. At each visit, partici-
pants were provided counseling to reduce the risks of drug use. The Risk
Evaluation Assessment of Community Health protocol and the HCV sub-
study protocols were approved by the institutional review boards of the
Johns Hopkins Schools of Medicine and Hygiene and Public Health.
From 1997 to 2002, 179 participants were enrolled and 62 (34.6%) de-
veloped anti-HCV antibodies (seroconverted). Beginning in November
2001, acutely infected persons were assessed for donation of  108–1010 PB-
MCs by blood donation or apheresis. HCV-specific lymphocyte responses
and sequences were studied in detail in 5 acutely infected persons who were
assessed frequently during the 6-mo period after infection and from whom
large volumes of PBMCs were obtained. HCV sequencing and limited
analysis of the cellular response were performed using three additional sub-
jects for whom smaller numbers of cells were available, as described below.
All of the subjects were infected with subtype 1a virus except for subject 11,
who was infected with a subtype 1b virus. The class I HLA types for each
subject are shown in Table III.
HCV testing protocol
Serum or plasma, stored at  80 C, from monthly follow-up visits was
tested for the presence of HCV-specific antibodies using the commercially
available Ortho version 3.0 ELISA (Ortho Clinical Diagnostics) according
to manufacturer’s instructions. Specimens in which antibodies were de-
tected were retested in duplicate along with the participant’s previous se-
ronegative sample to identify seroconverters.
HCV RNA testing was performed on sera or plasma that was separated
from blood within 2 h of collection and stored at  80 C. For HCV sero-
converters, HCV RNA testing was done on samples that were collected be-
fore seroconversion until a negative result was obtained, and after serocon-
version to evaluate the outcome of infection (viral persistence versus
clearance) by using quantitative, and if undetectable, qualitative HCV RNA
tests that are described below.
HCV RNA assays
Qualitative. For detecting HCV RNA, we used the COBAS AMPLI-
COR Hepatitis C Virus Test version 2.0 (Roche Molecular Systems). A limit
of detection of 1.7 log10 IU/ml at  95% detection is reported for this assay.
Quantitative. To determine the concentration of HCV RNA in serum,
we used a quantitative RT-PCR assay (COBAS AMPLICOR HCV Mon-
itor version 2.0; Roche Molecular Systems). This assay has a lower limit of
quantitation of 2.8 log10 IU/ml. When HCV RNA was not detected by us-
ing this assay, the sample was retested using the Roche qualitative test.
HCV genotyping. Genotype was determined by performing phyloge-
netic analysis on Core-E1 region sequences of HCV that was obtained from
the first viremic specimen. For most specimens, sequences were obtained
from cDNA clones that were generated with a long amplicon RT-PCR
method that was described previously (50). For other specimens, genotype
was determined by direct sequencing of RT-PCR products from the same
Core-E1 region as described previously (51). Sequences were aligned using
Table III. HLA alleles of the study subjects
Subject HLA A HLA B HLA C 
11 A*0202, A*7401 B*3524, B*5703 C*0401, C*0701
12 A*3303, A*3601 B*1503, B*5301 C*0202, C*0401
13 A*3001, A*7401 B*3501, B*4201 C*1601, C*1701
17 A*0201, A*0301 B*3503, B*5101 C*0401, C*1402
18 A*0201, A*0201 B*5501, B*4403 C*0303, C*0401
21 A*3303, A*6601 B*3501, B*5801 C*0302, C*0401
28 A*0201, A*0101 B*0801, B*3701 C*0701, C*0602
29 A*0101, A*0201 B*0801, B*1302 C*0701, C*0602CELLULAR IMMUNE SELECTION AND HCV PERSISTENCE | Cox et al. 1750
ClustalX (52), and trimmed to equal length using BioEdit (53). The
GTR I G analytical model (parameters available on request from the au-
thors) was selected using the Akaike information criterion as implemented
in ModelTest version 3.06 (54) and PAUP* version 4b10 (Sinauer Associ-
ates). Phylogenetic trees were estimated using the neighbor-joining algo-
rithm implemented in PAUP*, and robustness of clustering was tested by
using bootstrap analysis (55).
Viral recovery
HCV clearance was defined as the presence of anti-HCV with HCV RNA
undetectable by the COBAS AMPLICOR qualitative assay in serum or
plasma specimens from at least two consecutive visits that were obtained at
least 300 d after the initial detection of viremia. Persistence was defined as
the persistent presence of anti-HCV with HCV RNA detectable by the
qualitative or quantitative COBAS AMPLICOR assay in serum or plasma
specimens that were obtained at least 300 d after initial viremia (56).
Hemigenomic HCV sequencing and analysis
The 5.2-kb region from the 5  UTR to the NS3/NS4A junction was
cloned from 140–280  L of serum or plasma as described previously (50).
For each specimen, 33 clones were assigned to clonotypes by using a previ-
ously described gel shift assay (57); 2 clones that represented the modal
clonotype were sequenced, with a third clone used as needed to resolve dis-
crepancies. Sequences were assembled into contigs using Aligner (Codon-
Code). Sequence data were obtained at the point of initial viremia and ap-
proximately 6 mo later. These sequences have been submitted to GenBank/
EMBL/DDBJ with accession nos. DQ061296–DQ061330.
Reference sequence analysis
Reference sequence data were obtained from the HCV Sequence Database
(http://hcv.lanl.gov). For Table 1, the amino acid sequence was inferred
from cDNA sequences, which were obtained using the HCV Sequence Da-
tabase’s search interface. Default search parameters were used, except that:
(a) only subtype 1a sequences were included, (b) recombinant sequences
were excluded, (c) nonhuman sequences were excluded, and (d) the search
was performed for the codon of interest based on position in the HCV
polyprotein. When multiple sequences with the same “patient ID” were
obtained, only the first occurrence was retained.
Cellular immunology
IFN-  ELISPOT assay to assess HCV-specific T cell responses.
HCV-specific CD8  T cell responses were quantified by ELISPOT assay as
described previously (58) with the following modifications. For subjects 17,
18, 21, 28, and 29, enough PBMCs were acquired to test for T cell recog-
nition of 523 overlapping peptides (16-22-mer peptides overlapping by 10
amino acids) spanning the entire expressed HCV-H77 genome (genotype
1a) as well as 83 peptides that corresponded to optimal described CTL
epitopes (59) in a matrix format. The peptides that were recognized in the
matrix were tested individually and in at least duplicate to confirm recogni-
tion and to measure the number of spot-forming colonies (SFCs) that were
produced. For three additional subjects where the number of cells was lim-
ited, responses to peptides spanning regions of sequence variation detected
during sequencing, but not to the entire collection of 523 overlapping pep-
tides, were assessed. 96-well polyvinylidene plates (Millipore) were coated
with 2.5  g/ml recombinant human anti–IFN-  antibody (Endogen,
Pierce Biotechnology) in PBS at 4 C overnight. Fresh or previously frozen
PBMCs were added at 200,000 cells/well in 140  l R10 media (RPMI
1640 [Sigma-Aldrich], 10% FCS [Sigma-Aldrich], and 10 mM Hepes buffer
[Sigma-Aldrich] with 2 mM glutamine and antibiotics [50 U/ml penicillin-
streptomycin]). Peptides were added directly to the wells at a final concen-
tration of 10  g/ml. The plates were incubated for 20 h at 37 C, 5% CO2.
Plates were washed, labeled with 0.25  g/ml biotin-labeled anti-IFN- 
(Endogen), and developed by incubation with streptavidin-alkaline phos-
phatase (Bio-Rad Laboratories) followed by incubation with 5-bromo-
4-chloro-3-indolyphosphate/nitroblue tetrazolium chloride (Bio-Rad Lab-
oratories) in Tris-buffer, pH 9.5. The reaction was stopped by washing with
tap water and the plates were dried, before counting on an ELISPOT reader
(Cellular Technology Ltd.). For quantitation of ex vivo responses, the assay
was performed at least in duplicate and background was not more than 15
SFCs per million PBMCs. Responses were considered positive if the num-
ber of spots per well minus the background was at least 25 SFCs per million
PBMCs (58). A control of pooled CMV, EBV, and influenza antigens (CEF
control peptide pool) and phytohemagglutinin were used as positive con-
trols (60). Responses to the CEF control peptide pool were quantifiable and
remained relatively constant over time. Responses to phytohemagglutinin
were uniformly positive.
Intracellular cytokine staining. To determine whether the lines gener-
ated for each epitope were CD4  or CD8  T cell lines, intracellular cyto-
kine staining for IFN-  was performed as described previously (58). In
brief, 1   106 PBMCs were incubated with 4  g/ml peptide at 37 C and
5% CO2 for 1 h before the addition of Monensin (1  l/ml; Sigma-Aldrich).
The cells were incubated for an additional 5 h at 37 C and 5% CO2. PB-
MCs were washed and stained with surface antibodies, FITC-conjugated
anti-CD8 or FITC-conjugated anti-CD4 (Becton Dickinson) at 4 C for 20
min. Following the washing, the PBMCs were fixed and permeabilized
(Caltag), and the PE-conjugated anti–IFN-  mAb (Becton Dickinson) was
added. Cells were washed and analyzed on a FACS-Calibur flow cytometer
using CellQuest software (Becton Dickinson).
Magnetic bead separation of CD8  and CD4  T cells. To deter-
mine if the responding T cells in PBMCs were CD4  or CD8  T cells, be-
tween 3 and 10   107 PBMCs were labeled with magnetic beads bearing
anti-CD8 or anti-CD4 antibodies (Miltenyi Biotec) according to the manu-
facturer’s instructions. Cells were positively selected using an Auto MACS
(Miltenyi Biotec) to isolate either CD8  or CD4  cells. The ELISPOT as-
say was repeated using the isolated CD8  or CD4  T cells to determine if
recognition of an epitope was mediated by CD8  or CD4  T cells.
Bulk stimulation of peripheral blood mononuclear cells. To estab-
lish CD8  T cell lines, cryopreserved or fresh PBMCs (4–10   106) were
stimulated with 10  g/ml of synthetic HCV peptide and 0.5  g/ml of the
costimulatory antibodies anti-CD28 and anti-CD49d (Becton Dickinson)
in R10 media. Recombinant IL-2 (25 IU/ml) was added on day 2 and ev-
ery other day thereafter. Cells were restimulated with 25   106 irradiated
allogeneic PBMCs and 10  g/ml of synthetic HCV peptide after 10 d.
Testing impact of amino acid substitutions on T cell recognition
To assess the impact of amino acid substitutions on T cell recognition,
HCV peptide–specific T cell lines generated from PBMCs that were ob-
tained 6 mo after initial viremia were tested for IFN-  production in re-
sponse to serial dilutions of synthetic peptides that represented the viral se-
quences which were present at initial viremia (t0) or at 6 mo after initial
viremia (t6). In four cases where the frequency of T cells that were specific
for the HCV epitope was high, bulk PBMCs that were obtained 6 mo after
initial viremia also were tested in this way. Comparison of initial and variant
epitopes was performed using log10 dilutions of the t0 and t6 peptides from
10  M to 0.001 M in the IFN-  ELSIPOT assay that was described above
for PBMCs, but using 30,000 T cells when T cell lines were tested. 10 pep-
tide pairs from subjects with chronic viremia were tested, and three patterns
were observed. Loss of recognition was defined as either no recognition at
the highest concentration of the t6 peptide or at least 20-fold greater recog-
nition of the t0 peptide than the t6 peptide at all concentrations. Decreased
recognition was defined as  2-fold, but  20-fold fewer SFCs produced at
two or more concentrations of the t6 peptide. Comparable recognition was
defined as no more than a twofold difference in SFC between the t0 and t6
peptides at two or more concentrations tested.
MHC-peptide binding assays. EBV-transformed cell lines were used as
the primary sources of HLA molecules. Cells were maintained in vitro andJEM VOL. 201, June 6, 2005 1751
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HLA molecules were purified by affinity chromatography as described pre-
viously (61). Quantitative assays to measure the binding of peptides to puri-
fied class I molecules are based on the inhibition of binding of a radiolabeled
standard peptide (61). In brief, 1–10 nM of radiolabeled peptide was coin-
cubated at room temperature with 1  M to 1 nM of purified MHC in the
presence of 1  M human  2-microglubulin (Scripps Laboratories) and a
cocktail of protease inhibitors. After a 2-d incubation, binding of the radio-
labeled peptide to the corresponding MHC class I molecule was determined
by capturing MHC/peptide complexes on Greiner Lumitrac 600 micro-
plates (Greiner Bio-one) that were coated with the W6/32 antibody, and
measuring bound cpm using the TopCount microscintillation counter
(Packard Instrument Co.).
Statistical analysis
Statistical analysis was done with the aid of SigmaStat software version 3.10
(Systat Software, Inc.). For comparing proportions, Fisher’s exact (small
sample size) and Chi squared (large sample size) tests were used. Differences
were considered significant if p-values were  0.05.
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